Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Substudy 2C (12 Healthy volunteers): GLP-1
研究概览
简要总结
The purpose of this study is to determine the role of inflammation and the insulin regulating hormone GLP-1 during critical illness.
详细描述
Critically ill patients often exhibit hyperglycaemia. Although the cause of this hyperglycaemia is probably multifactorial, peripheral insulin resistance is a major contributor, similar to type 2 diabetes mellitus (T2D). There are several similarities between critical illness and T2D, including the presence of systemic inflammation and increased plasma free fatty acids (FFA), all of which may induce insulin resistance in healthy volunteers. In critical illness, elevated catecholamines, cortisol, growth hormone and glucagon may also contribute to insulin resistance.
The degree of hyperglycaemia correlates with mortality in ICU patients. van den Berghe et al. found that IV infusion of insulin to obtain strict normoglycaemia reduced mortality as well as morbidity in critically ill surgical patients and in some medical ICU patients.
However, insulin increases the risk of hypoglycaemia; this is a major obstacle to strict euglycaemia in ICU patients and may explain the inability of others to reproduce the benefits reported by van den Berghe et al. Thus, alternatives to insulin for controlling plasma glucose (PG) in ICU patients are warranted.
Aim:
To study the role of the incretin hormone, glucagon-like peptide (GLP)-1 for glycaemic, metabolic, hormonal and inflammatory profile in
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years(Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
2A-3
TNF and OGTT
干预措施: OGTT (Other)
2C - 1
TNF and OGTT and saline
干预措施: Placebo (Saline) (Drug)
2C - 1
TNF and OGTT and saline
干预措施: TNF-alfa (Drug)
2C - 1
TNF and OGTT and saline
干预措施: OGTT (Other)
2C - 2
TNF and OGTT and GLP-1
干预措施: TNF-alfa (Drug)
2C - 2
TNF and OGTT and GLP-1
干预措施: OGTT (Other)
2C - 3
TNF and IVGTT and saline
干预措施: Placebo (Saline) (Drug)
2C - 3
TNF and IVGTT and saline
干预措施: TNF-alfa (Drug)
2C - 3
TNF and IVGTT and saline
干预措施: IVGTT (Other)
2C - 4
TNF and IVGTT and GLP-1
干预措施: TNF-alfa (Drug)
2C - 4
TNF and IVGTT and GLP-1
干预措施: IVGTT (Other)
2A-1
Saline infusion and OGTT
干预措施: Placebo (Saline) (Drug)
2A-1
Saline infusion and OGTT
干预措施: OGTT (Other)
2A-2
Saline and IVGTT
干预措施: Placebo (Saline) (Drug)
2A-2
Saline and IVGTT
干预措施: IVGTT (Other)
2A-3
TNF and OGTT
干预措施: TNF-alfa (Drug)
2A-4
TNF and IVGTT
干预措施: TNF-alfa (Drug)
2A-4
TNF and IVGTT
干预措施: IVGTT (Other)
1C
OGTT and corresponding IVGTT
干预措施: OGTT (Other)
1C
OGTT and corresponding IVGTT
干预措施: IVGTT (Other)
2C - 4
TNF and IVGTT and GLP-1
干预措施: GLP-1 (Drug)
2C - 2
TNF and OGTT and GLP-1
干预措施: GLP-1 (Drug)
结局指标
主要结局
Substudy 2C (12 Healthy volunteers): GLP-1
时间窗: 6 weeks after intervention
Increased plasma insulin and C-peptide (intact insulinotropic effect of GLP-1) during GLP-1 infusion in healthy volunteers.
Substudy 2A (12 Healthy volunteers): Insulin, C-peptide and incretin hormone response
时间窗: 6 weeks after intervention
Insulin, c-peptide and incretin hormone response to glucose stimulation during standardized systemic inflammation (TNF infusion) compared to placebo (saline infusion)
Substudy 1C(8 patients, 8 healthy controls): Insulin, C-peptide and incretin hormone response
时间窗: 6 weeks after intervention
Insulin, c-peptide and incretin hormone response to glucose stimulation during IVGTT compared to OGTT in critically ill patients admitted to the ICU
次要结局
- Substudy 2C (12 Healthy volunteers): Clamp(6 weeks after intervention)
- Substudy 2A (12 Healthy volunteers): The incretin effect(6 weeks after intervention)
- Substudy 1C (8 patients, 8 healthy controls): The incretin effect(6 weeks after intervention)
研究者
Kirsten Moller
MD, PH.D, DMSc
Rigshospitalet, Denmark
